Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil for chronic lung allograft dysfunction after bilateral lung transplantation
2023-503462-23-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in chronic lung allograft dysfunction (CLAD) and Lung allograft rejection (LAR) comparing Belumosudil with Placebo (2 arms). Primary endpoint: Percent change from baseline to Week 26 in FEV1. Planned start Dec 2023; status: authorised.
02
Drugs
belumosudil
03
Conditions
chronic lung allograft dysfunction (CLAD)Lung allograft rejection (LAR)
Beyond the preview
Go deeper on 2023-503462-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503462-23-00.